EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Long‐Term Treatment With Emapalumab in an Adult Patient With Refractory Hemophagocytic Lymphohistiocytosis and Systemic Lupus Erythematosus: A Case Report

Hind Salama iD, Ghada Alshehri iD, Ayel Yahya iD, Areej Almugairi iD

Case Reports in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/crh/7722625 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Hematology, online erschienen am 09.07.2026. Verfasst von Hind Salama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Division of Adult Hematology, King Abdulaziz Medical City, Riyadh, Saudi Arabia, ngha.med.sa. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome characterized by excessive immune activation due to persistently activated cytotoxic lymphocytes and macrophages. HLH can lead to multiorgan dysfunction and can be fatal if left untreated. HLH secondary to autoimmune diseases is referred to as macrophage activation syndrome (MAS). Case Presentation A female Arab Saudi patient in her late 20s with a history of systemic lupus erythematosus (SLE) presented with reduced oral intake, abdominal pain, decreased urine output, tachypnea, shortness of breath, and acute heart failure. MAS secondary to SLE and associated stress cardiomyopathy was suspected. Despite initial treatment with the HLH‐94 protocol, the patient showed no improvement and developed Gram‐negative septicemia with worsened cytopenia. Emapalumab, a monoclonal antibody that targets interferon gamma (IFN‐γ), was introduced as a salvage therapy, resulting in rapid clinical and biochemical improvement, including normalization of cardiac function. The patient received emapalumab for around 17 months, with good tolerability apart from a brief period of CMV reactivation, achieving sustained remission. Following discontinuation, HLH recurred in the context of newly diagnosed myelodysplastic syndrome and was refractory to conventional therapy but responded again to emapalumab retreatment. At the time of last follow‐up, the patient remained clinically stable with no evidence of active HLH while continuing emapalumab therapy in the context of ongoing treatment for her underlying conditions.

Conclusions

This case report highlights the potential of emapalumab as an effective therapeutic option for the treatment of relapsed/refractory HLH in adults, including in SLE‐ and malignancy‐associated disease not responding to conventional therapy. It supports its role in achieving rapid disease control, enabling prolonged remission with extended use, and allowing successful retreatment in recurrent HLH, including in high‐risk settings with poor outcomes such as malignancy‐associated HLH.

Schlagwörter

Stichwörter der Autor:innen

case reportemapalumabhemophagocytic lymphohistiocytosismacrophage-activation syndromemyelodysplastic syndromesystemic lupus erythematosus

Autor:innen und Institutionen

  • Department of Oncology, Division of Adult Hematology, King Abdulaziz Medical City, Riyadh, Saudi Arabia, ngha.med.sa.
  • College of Medicine, King Saud Bin Abdulaziz University, Riyadh, Saudi Arabia, ksau-hs.edu.sa.
  • King Abdullah Medical Research Center, Riyadh, Saudi Arabia.
  • Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia, ngha.med.sa.

ORCID-Profile: Hind Salama, Ghada Alshehri, Ayel Yahya, Areej Almugairi

Förderung

  • Swedish Orphan Biovitrum

Zitieren

APA

Salama, H., Alshehri, G., Yahya, A., & Almugairi, A. (2026). Long‐Term Treatment With Emapalumab in an Adult Patient With Refractory Hemophagocytic Lymphohistiocytosis and Systemic Lupus Erythematosus: A Case Report. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/7722625

Vancouver

Salama H, Alshehri G, Yahya A, Almugairi A. Long‐Term Treatment With Emapalumab in an Adult Patient With Refractory Hemophagocytic Lymphohistiocytosis and Systemic Lupus Erythematosus: A Case Report. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/7722625

BibTeX
@article{Salama2026,
  author = {Salama, Hind and Alshehri, Ghada and Yahya, Ayel and Almugairi, Areej},
  title = {Long‐Term Treatment With Emapalumab in an Adult Patient With Refractory Hemophagocytic Lymphohistiocytosis and Systemic Lupus Erythematosus: A Case Report},
  journal = {Case Reports in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crh/7722625}
}
Kostenlos starten →